ClinicaliQ Trial Snapshot
- A Study of AAVB-039 in Participants With Stargardt Disease (STGD1) — Recruiting • Phase I / Phase II • NCT07161544.
- Gene therapy injection for Stargardt disease shows safety and early effectiveness in patients with ABCA4 gene mutations.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of the 039-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-039 in participants with Stargardt disease secondary to a biallelic mutation of the ABCA4 gene. The study will also assess initial efficacy following AAVB-039 administration. Conditions: Stargardt Disease Interventions: AAVB-039 Lead Sponsor: AAVantgarde Bio Srl Planned Enrollment: 75 participants